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ORIGINAL ARTICLE

Targeted therapy for advanced salivary gland carcinoma based on molecular
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Background: Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study,
evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present the
efﬁcacy and safety results for a subgroup of MyPathway patients with advanced salivary gland cancer (SGC) matched to
targeted therapies based on tumor molecular characteristics.
Patients and methods: MyPathway is an ongoing, multiple basket, open-label, non-randomized, multi-center study.
Patients with advanced SGC received pertuzumab þ trastuzumab (HER2 alteration), vismodegib (PTCH-1/SMO
mutation), vemurafenib (BRAF V600 mutation), or atezolizumab [high tumor mutational burden (TMB)]. The primary
endpoint is the objective response rate (ORR).
Results: As of January 15, 2018, 19 patients with SGC were enrolled and treated in MyPathway (15 with HER2
ampliﬁcation and/or overexpression and one each with a HER2 mutation without ampliﬁcation or overexpression,
PTCH-1 mutation, BRAF mutation, and high TMB). In the 15 patients with HER2 ampliﬁcation/overexpression (with
or without mutations) who were treated with pertuzumab þ trastuzumab, 9 had an objective response (1 complete
response, 8 partial responses) for an ORR of 60% (9.2 months median response duration). The clinical beneﬁt rate
(deﬁned by patients with objective responses or stable disease >4 months) was 67% (10/15), median progressionfree survival (PFS) was 8.6 months, and median overall survival was 20.4 months. Stable disease was observed in
the patient with a HER2 mutation (pertuzumab þ trastuzumab, n ¼ 1/1, PFS 11.0 months), and partial responses in
patients with the PTCH-1 mutation (vismodegib, n ¼ 1/1, PFS 14.3 months), BRAF mutation (vemurafenib, n ¼ 1/1,
PFS 18.5 months), and high TMB (atezolizumab, n ¼ 1/1, PFS 5.5þ months). No unexpected toxicity occurred.
Conclusions: Overall, 12 of 19 patients (63%) with advanced SGC, treated with chemotherapy-free regimens matched to
speciﬁc molecular alterations, experienced an objective response. Data from MyPathway suggest that matched targeted
therapy for SGC has promising efﬁcacy, supporting molecular proﬁling in treatment determination.
Key words: advanced salivary gland carcinoma, targeted therapy, HER2-positive, pertuzumab, trastuzumab, molecular
proﬁling

INTRODUCTION
The incidence of salivary gland cancer (SGC) has risen from
10.4 per 1 000 000 in 1973 to 16 per 1 000 000 in 2009.1
Advanced salivary gland carcinomas are particularly unresponsive to traditional chemotherapies.2 No standard of
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care for systemic therapy exists for metastatic disease,2 and
no treatments have been approved by the USA Food and
Drug Administration (FDA) speciﬁcally for SGC. As such,
patients with advanced SGC have a clear unmet need for
effective systemic treatment options.
SGCs have high heterogeneity in their molecular and
genomic characteristics and commonly harbor potentially
actionable alterations.36 Human epidermal growth factor
receptor 2 (HER2) alterations, for example, are particularly
prevalent in aggressive or high-grade tumor subtypes,
including salivary duct carcinoma (SDC) and other salivary
carcinomas.6,7 Other potentially targetable alterations include
PIK3CA and BRAF mutations, tumor mutational burden (TMB)
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>10 mutations/Mb, and NTRK3 gene fusion, among others.6
Therapies targeting these molecular characteristics have
demonstrated success in other cancer types, making SGC a
prime candidate for existing targeted treatments.
Recent reports have suggested potential for targeted
treatment of SGC. A phase II trial of patients with HER2positive SDC reported a response rate of 70.2% following
treatment with trastuzumab þ docetaxel, although 60% of
patients experienced grade 4 decreased neutrophil count.8
Encouraging results have also been observed anecdotally
with targeted regimens free of traditional chemotherapy,
including almost complete disease resolution in a heavily
pretreated patient with HER2-ampliﬁed and overexpressing
SDC treated with trastuzumab þ lapatinib þ bevacizumab,9
and a patient with HER2-overexpressing metastatic SDC
treated with second-line trastuzumab emtansine (T-DM1)
who experienced a prolonged response with low toxicity.10
Vemurafenib, a BRAF inhibitor approved for the treatment
of patients with melanomas or ErdheimeChester disease
harboring BRAF V600 mutations, produced a complete
response in a patient with BRAF V600-mutated SDC.11 Finally,
treatment of TRK fusion-positive salivary tumors with the
tyrosine receptor kinase inhibitors entrectinib and larotrectinib have resulted in complete and partial responses.12,13
MyPathway (NCT02091141), an ongoing, multiple basket,
phase IIa study, evaluates the efﬁcacy of established,
chemotherapy-free targeted therapies for non-approved indications in patients with advanced solid tumors harboring
potentially actionable genetic or molecular alterations.14
Eligible alterations include HER2 ampliﬁcation, overexpression, and/or mutations (treated with pertuzumab þ
trastuzumab); Hedgehog pathway alterations (PTCH-1 or
SMO mutations, treated with vismodegib); BRAF V600 mutations (treated with vemurafenib  cobimetinib); high microsatellite instability, high TMB, or deﬁcient mismatch
repair (treated with atezolizumab); ALK genetic alterations
(treated with alectinib); or EGFR-activating mutations
(treated with erlotinib). This trial design allows MyPathway
to address treatment efﬁcacy in both common and rare
tumor types, regardless of their site of origin. Here, we
present the efﬁcacy and safety results for the subgroup of
MyPathway patients with advanced SGC treated on the basis
of their molecular characteristics with pertuzumab þ trastuzumab, vismodegib, vemurafenib, or atezolizumab.
METHODS
Study design and participants
MyPathway is a multiple basket, open-label, non-randomized, multi-center phase IIa trial of patients with treatmentrefractory advanced solid tumors with potentially predictive
molecular alterations (see supplementary Figure S1, available at Annals of Oncology online). Patients in this analysis
were enrolled from 12 sites and had advanced SGC with
HER2 ampliﬁcation, overexpression, and/or mutations; a
Hedgehog pathway alteration; a BRAF V600 mutation; or
high TMB (by FoundationOne). Molecular alterations were
locally assessed by Clinical Laboratory Improvement
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Amendments certiﬁed laboratory tests, as determined by
the treating physician before enrollment, and reviewed by a
study medical monitor for eligibility. Patients were aged
18 years, had measurable or evaluable lesions, and had an
Eastern Cooperative Oncology Group (ECOG) performance
status score of 2. Patients with active brain metastases,
concurrent active anti-cancer therapy, pregnancy, or contraindications to study therapy were excluded.
The primary endpoint is objective response rate (ORR);
secondary endpoints include clinical beneﬁt rate [CBR;
deﬁned as the percentage of patients who achieved an
objective response or stable disease (SD) >4 months],
duration of response, progression-free survival (PFS), overall
survival (OS), and safety. Exploratory analyses include the
molecular characterization of tumor biomarkers.
MyPathway is conducted in accordance with the International Conference on Harmonisation Guideline for Good
Clinical Practice and the Declaration of Helsinki. The protocol was approved by the institutional review board or
ethics committee at each trial center. Patients provided
written informed consent before screening.
Procedures and assessments
Patients were treated in accordance with the United States
package inserts1519 without systemic chemotherapy. Those
with HER2 ampliﬁcation, overexpression, and/or mutation
received pertuzumab [840 mg intravenous infusion (i.v.)
loading dose, followed by 420 mg i.v. every 3 weeks (q3w)] plus
trastuzumab (8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v.
q3w). Patients with a Hedgehog pathway alteration (PTCH-1 or
SMO mutation) were administered vismodegib (150 mg orally
once daily in 28-day cycles). Patients with BRAF V600 mutations received vemurafenib (960 mg orally twice daily in 28-day
cycles). Finally, patients with high TMB received atezolizumab
(1200 mg i.v. q3w). Tumor burden was investigator-evaluated.
Treatments were administered until disease progression, unacceptable toxicity, or other discontinuation criteria were met.
Details regarding tumor assessments and molecular proﬁling
methodology are available in the supplementary Methods,
available at Annals of Oncology online.
Statistical analysis
The ClopperePearson estimation method was used to
calculate 95% conﬁdence intervals (CIs) for ORR and CBR.
Median PFS, OS, duration of response [in patients with
complete response (CR) or partial response (PR)], and their
95% CIs were estimated using the KaplaneMeier approach.
Additional information on clinical outcome endpoints and
planned sample size are provided in the supplementary
Methods, available at Annals of Oncology online.
RESULTS
Patients
As of the data cutoff (15 January 2018), 19 patients with
SGC were enrolled in MyPathway (supplementary Figure S2,
available at Annals of Oncology online). Sixteen patients
https://doi.org/10.1016/j.annonc.2019.11.018
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received pertuzumab þ trastuzumab, of whom 15 had HER2
ampliﬁcation and/or overexpression [with HER2 mutations
in two patients (G776V and L755F plus D769H)] and one
had a HER2 mutation (S310F) without ampliﬁcation or
overexpression (Table 1). The other three patients received
vismodegib (n ¼ 1, truncating PTCH-1 Q400* mutation),
vemurafenib (n ¼ 1, BRAF V600E mutation), or atezolizumab (n ¼ 1, high TMB of 31 mut/Mb). All treated patients
were evaluable for efﬁcacy.
All 19 patients had aggressive salivary gland carcinomas
(salivary gland adenocarcinoma, n ¼ 11; high-grade
mucoepidermoid carcinoma, n ¼ 4; and unspeciﬁed carcinoma, n ¼ 4). The median age was 61 (range, 37e82) years
and patients received a median of one (range, 1e3) previous systemic treatment regimen. Most patients were male
[n ¼ 16 (84%)], white [n ¼ 14 (74%)], and had an ECOG
performance status score of 1 [n ¼ 17 (89%)] (Table 1).
Clinical outcomes
The median follow-up duration was 10.6 (range, 3e26)
months. Nine of 15 patients with HER2 ampliﬁcation and/or
overexpression had objective responses to treatment with
pertuzumab þ trastuzumab (one CR, eight PRs) for an ORR
of 60% (95% CI 32% to 84%) (Table 2). One additional patient had SD for 11.7 months [CBR 67% (n ¼ 10), 95% CI
38% to 88%]. Treatment duration ranged from 0.7 to 26.1
[ongoing (þ)] months and estimated median response
duration in patients with an objective response was 9.2
(range, 1.4þ to 19.7þ) months, with ﬁve out of nine responses (including the CR) ongoing at the time of data
cutoff. Time on treatment and best change in target lesion
size by patient are shown in Figure 1A,B. By the data cutoff,
nine patients with HER2 ampliﬁcation and/or overexpression had progressed or died (Table 2). Median PFS
was 8.6 [95% CI 2.3 to not estimable (NE)] months
(Figure 2A) and median OS was 20.4 (95% CI 8.2 to NE)
months (Figure 2B).
One patient with a HER2 S310F mutation without
ampliﬁcation or overexpression had SD lasting 11.0 months
as the best response following treatment with
pertuzumab þ trastuzumab (Table 2). The patients with a
PTCH-1 Q400* mutation (treated with vismodegib) and
BRAF V600E mutation (treated with vemurafenib) experienced PRs lasting 10.7 and 15.1 months but had discontinued treatment due to clinical progression and
progressive disease by the data cutoff, respectively. Finally,
following SD of 5.4 months, a PR was reported in the
atezolizumab-treated patient with high TMB (31 mut/Mb)
at the last tumor assessment before the data cutoff; the
patient remained on treatment.
Overall, 12 of 19 patients (63%) achieved an objective
response when matched to therapy based on the genomic
characteristics of their tumors. Including patients with SD
>4 months, 14 of 19 patients (74%) experienced clinical
beneﬁt. Median PFS for all 19 patients was 11.7 months
(95% CI 5.6% to 18.5%) and median OS was 20.4 months
(95% CI 9.1 to NE). Case reports for one patient in each
414
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treatment arm are presented in the supplementary Results
and Figures S3eS6, available at Annals of Oncology online.
Tumor molecular proﬁles
Genomic proﬁling data were available for 11 of 15 patients
with HER2 ampliﬁcation and/or overexpression, and all
patients in the remaining cohorts (see supplementary
Table S1, available at Annals of Oncology online). Mutational proﬁles are shown in Figure 3 and described in detail
in the supplementary Results, available at Annals of
Oncology online.
Safety
Of 16 patients treated with pertuzumab þ trastuzumab,
treatment-emergent adverse events (TEAEs) and TEAEs
thought to be related to one or both study drugs were
reported in 94% (n ¼ 15) and 88% (n ¼ 14) of patients,
respectively. Serious TEAEs and grade 3e4 TEAEs were
observed in 13% (n ¼ 2) and 25% (n ¼ 4) of patients,
respectively, with no serious or grade 3e4 TEAEs experienced by more than one patient. There were no deaths due
to a TEAE. The most common drug-related TEAEs were
diarrhea [50% (8/16)], pruritus [31% (5/16)], and chills [25%
(4/16)] (see supplementary Table S2, available at Annals of
Oncology online). One patient had grade 3 peripheral
neuropathy considered related to the study drugs
(supplementary Table S3, available at Annals of Oncology
online). Of the three reported grade 4 TEAEs, none were
considered related to the study drugs.
Each of the patients treated with vismodegib, vemurafenib, and atezolizumab experienced TEAEs, including at
least one grade 3 TEAE. TEAEs thought to be related to the
study drugs and serious TEAEs were reported in the vismodegib and vemurafenib-treated patients. Grade 3 drugrelated TEAEs included diarrhea, decreased weight, and
hypokalemia in the vismodegib-treated patient, and maculopapular rash in the vemurafenib-treated patient. No
TEAEs higher than grade 3 were observed.
DISCUSSION
SGCs are refractory to many common chemotherapeutic
treatments, but few studies have been conducted to identify effective systemic therapies due to the rarity of the
disease. Data from MyPathway support the potential of
chemotherapy-free targeted therapy for patients with
advanced SGC. We observed promising efﬁcacy in the
subgroup of patients with HER2-ampliﬁed and/or overexpressing salivary gland carcinomas treated with
pertuzumab þ trastuzumab, the largest cohort assessed in
this analysis [ORR, 60% (95% CI 32% to 84%); CBR, 67%
(95% CI 38% to 88%); median PFS, 8.6 (95% CI 2.3 to NE)
months; median OS, 20.4 (95% CI 8.2 to NE) months]. Responses were durable (median 9.2 months), and ﬁve of nine
were ongoing at data cut off, including the CR. Furthermore,
we observed promising results in individual patients with
tumors harboring a HER2 S310F mutation (pertuzumab þ
trastuzumab; SD, 11.0 months); a PTCH-1 Q400* mutation
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Pt

Sex

Age, years

Race

ECOG PS

Histology

-

Issue 3

Stage

Alteration

Testing platforma

G3
G2
G3

IV
IVA
IVA

G4

IV

HER2 ampliﬁcation
HER2 overexpression
HER2 ampliﬁcation þ
overexpression
HER2 ampliﬁcation þ
overexpression
HER2 ampliﬁcation þ
overexpression
HER2 ampliﬁcation,
overexpression þ mutation

NGS (copy number ¼ 15)
IHC (3þ)
FISH/CISH (ratio ¼ 7.3), IHC
(3þ)
FISH/CISH (ratio ¼ 2.4), IHC
(3þ)
FISH/CISH (ratio ¼ 9.9), IHC
(3þ)
NGS (copy number gain;
L755F and D769H
mutations), IHC (3þ)
NGS (copy number ¼ 94);
IHC (3þ)
NGS (copy number ¼ 104),
IHC (3þ)
FISH/CISH (ratio ¼ 5.5),
NGS (G776V mutation)
NGS (copy number gain)
NGS (copy number ¼ 60)

Previous lines
of therapyb

Sites of metastasis

4

M

70

overexpression: treated with pertuzumab D trastuzumab
White
0
Salivary duct adenocarcinoma
White
1
Adenocarcinoma
Black/African
2
Unspeciﬁed carcinoma
American
White
1
Invasive ductal carcinoma

5

M

73

White

1

Adenocarcinoma

G3

IV

6

M

47

White

1

Adenocarcinoma

G3

IVC

7

M

61

White

1

Unspeciﬁed carcinoma

G3

III

8

F

54

White

0

Adenocarcinoma

G3

IV

9

M

54

Other

1

Unspeciﬁed carcinoma

G3

III

HER2 ampliﬁcation þ
overexpression
HER2 ampliﬁcation þ
overexpression
HER2 ampliﬁcation þ mutation

10
11

F
M

75
70

Asian
White

0
1

Adenocarcinoma
Unspeciﬁed carcinoma

G3
G1

IVA
IVC

HER2 ampliﬁcation
HER2 ampliﬁcation

12
13

M
M

37
62

1
1

Adenocarcinoma
Mucoepidermoid carcinoma

GX
G3

IV
III

HER2 overexpression
HER2 ampliﬁcation þ
overexpression

IHC (3þ)
FISH/CISH (ratio ¼ 7.8),
NGS (copy number ¼ 20),
IHC (3þ)

1
3

14

M

48

White
American
Indian
or Alaska
native
Asian

Lung
Bone, liver, lung, LN,
intraorbital
Bone, liver
Adrenal gland, liver, lung, LN

1

Invasive ductal carcinoma

G4

IVA

Brain, lung, LN

F

44

White

2

Adenocarcinoma

G3

IV

FISH/CISH (ratio ¼ 7.2), IHC
(3þ)
NGS (copy number ¼ 15)

1

15

HER2 ampliﬁcation þ
overexpression
HER2 ampliﬁcation

2

Brain, chest wall, left eye, liver,
LN, neck (subcutaneous tissue),
parapharyngeal mucosa

G3

III

HER2 mutation

NGS (S310F mutation)

0

Lung, LN, mediastinum

G3

II

Hh alteration

NGS (PTCH-1 Q400*
mutation)

0

Lung

Mucoepidermoid carcinoma

G3

IV

BRAF mutation

NGS (V600E mutation)

1

Liver, lung, LN

Mucoepidermoid carcinoma

G3

IVA

High TMB

NGS (31 mutations/Mb)

0

Adrenal gland, LN, skin

HER2
1
2
3

ampliﬁcation and/or
M
59
M
80
M
55

-

2020

Grade

BRAF V600 mutation: treated with vemurafenib
18 M
51
White
1
High TMB: treated with atezolizumab
19 M
82
White
1

Brain, lung, LN
Bone, LN
Bone, lung, LN

1

Bone, liver, LN

1

Bone, LN, spleen

0

Bone, LN

0

Liver, lung

0

Liver, LN

0

Bone, lung, LN

0
2

ECOG PS, Eastern Cooperative Oncology Group performance status; F, female; FISH/CISH, ﬂuorescence/chromogenic in situ hybridization; HER2, human epidermal growth factor receptor 2; Hh, Hedgehog; IHC, immunohistochemistry; LN, lymph
node; M, male; NGS, next-generation sequencing; Pt, patient; PTCH-1, patched homolog-1; TMB, tumor mutational burden.
a
Not all patients were tested with all testing methods. Details from testing results are included, where available.
b
Previous regimens consisted of systemic chemotherapy in all patients.
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HER2 mutation: treated with pertuzumab D trastuzumab
16 M
68
White
0
Adenocarcinoma
Hh alteration: treated with vismodegib
17 M
65
White
0
Mucoepidermoid carcinoma

1
1
2
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Table 1. Baseline demographics and clinical characteristics by patient

Pt

Alteration

https://doi.org/10.1016/j.annonc.2019.11.018

Time on
treatment,
months

Best
response

HER2 ampliﬁcation and/or overexpression: treated with pertuzumab D trastuzumab
1
HER2 ampliﬁcation
16.5þ
CR
2
HER2 overexpression
26.1þ
PR
3
HER2 ampliﬁcation and overexpression
12.6
PR
4
HER2 ampliﬁcation and overexpression
8.3
PR
5
HER2 ampliﬁcation and overexpression
10.6þ
PR
6
HER2 ampliﬁcation, overexpression,
19.8
PR
and mutation (L755F and D769H)
7
HER2 ampliﬁcation and overexpression
4.1þ
PR
PR
8
HER2 ampliﬁcation and overexpression
4.1c
9
HER2 ampliﬁcation and mutation
3.5þ
PR
(G776V)
10
HER2 ampliﬁcation
11.2
SD
11
HER2 ampliﬁcation
3.5
SD
12
HER2 overexpression
2.9þ
SD
13
HER2 ampliﬁcation and overexpression
2.1
SD
14
HER2 ampliﬁcation and overexpression
0.7
PD
15
HER2 ampliﬁcation
0.7
PD
HER2 mutation: treated with pertuzumab D trastuzumab
16
HER2 mutation (S310F)
10.4
SD
Hh alteration: treated with vismodegib
17
Hh alteration (PTCH-1 Q400*)
14.4
PR
BRAF V600 mutation: treated with vemurafenib
18
BRAF mutation (V600E)
16.8
PR
High TMB: treated with atezolizumab
19
High TMB (31 mutations/Mb)
5.7þ
PR

Duration of
response,
months

Duration of SD,
months

Best change
in target lesion
size from
baseline, %

PFS, months

OS, months

15.2þ
19.7þ
9.2
7.3
7.2þ
4.2

e
e
e
e
e
e

91.7a
33.3
62.5
100.0b
66.7
85.7

16.5þ
25.2þ
13.4
8.6
8.5þ
5.6

16.5þ
26.1þ
20.4
14.9þ
10.6þ
21.2

2.8þ
2.7
1.4þ

e
e
e

73.0
68.2
55.7

4.0þ
9.1
2.8þ

4.1þ
9.1
3.5þ

e
e
e
e
e
e

11.7
3.9
2.9þ
2.3
e
e

27.9
25.6
24.3
1.4
3.6
22.5

11.7
3.9
2.9þ
2.3
1.5
1.4

14.0þ
10.4
2.9þ
8.2
8.3
3.1

e

11.0

12.8

11.0

13.7þ

55.6

14.3

17.3þ

10.7
15.1

e

43.4

18.5

20.1

0.03þ

e

56.0

5.5þ

5.7þ
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Table 2. Clinical outcomes by patient

CR, complete response; HER2, human epidermal growth factor receptor 2; Hh, Hedgehog; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; Pt, patient; PTCH-1, patched homolog-1; SD, stable
disease; TMB, tumor mutational burden. þ indicates measure was ongoing at the most recent assessment.
a
Patient’s target lesions were both lymph nodes with a measurement of <10 mm and absent/normal status of non-target lesions following treatment cycle 12, considered a CR per RECIST v1.1.
b
Patient had a 100% reduction in the target lesion but had a remaining non-target lesion and therefore did not qualify for a CR per RECIST v1.1.
c
Patient had an ongoing tumor response but withdrew from treatment and later died.
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Figure 1. (A) Time on treatment and (B) best change in target lesion size by patient (n ¼ 19).a
CR, complete response; HER2, human epidermal growth factor receptor 2; Hh, Hedgehog; PD, progressive disease; PR, partial response; PTCH-1, patched homolog-1;
SD, stable disease; TMB, tumor mutational burden.
a
Lanes represent individual patients.
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Figure 2. (A) Progression-free survival and (B) overall survival in patients with HER2 ampliﬁcation and/or overexpression (n [ 15).
HER2, human epidermal growth factor receptor 2.

418

https://doi.org/10.1016/j.annonc.2019.11.018

Volume 31

-

Issue 3

-

2020

R. Kurzrock et al.

Annals of Oncology

Figure 3. Mutational proﬁle of selected oncogenic alterations in patients with advanced salivary gland carcinoma (n [ 19).
BOR, best overall response; CR, complete response; HER2, human epidermal growth factor receptor 2; PD, progressive disease; PR, partial response; SD, stable disease;
TMB, tumor mutational burden.

(vismodegib; PR, 10.7 months); a BRAF V600E mutation
(vemurafenib; PR, 15.1 months); and high TMB (atezolizumab; PR as of the data cutoff date, following a prolonged SD
of 5.4 months).
Management of early SGC typically involves surgery or
radiotherapy, with no standard of care for the systemic
treatment of advanced cancer.2 Previously investigated
chemotherapeutic regimens were associated with low
response rates and high toxicity.20 Although the recent
phase II study of trastuzumab þ docetaxel in patients with
HER2-positive SDC produced a high response rate, more
than half of the patients experienced grade 4 decreased
neutrophil count.8 In MyPathway, we observed a response
rate of 60% with pertuzumab þ trastuzumab in patients
with HER2-ampliﬁed and/or overexpressing advanced SGCs.
This chemotherapy-free regimen was well tolerated, with
only one grade 3 TEAE considered to be related to the study
drugs, and no grade 4 related TEAEs. The median 20.4month OS in this cohort compares favorably with the 15month OS previously observed after the development of
distant metastases in patients with salivary gland carcinomas unselected for HER2 status.21 Finally, while the rarity
of SGC limited the assessment of vismodegib, vemurafenib,
and atezolizumab in only one patient each, the preliminary
observations of extended PRs or SDs in each of these patients, all of whom had recurrent disease after previous
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treatment of salivary cancer, suggest that patients can be
successfully matched to a variety of targeted therapies
based on the genomic characteristics of the tumors.
All 19 patients with SGC enrolled in the MyPathway study
had high-grade carcinomas. While genomic and molecular
alterations associated with adverse outcomes are common
in such tumors,6 some of the reported alterations are
potentially targetable with currently available agents,
providing new opportunities for the treatment of these
challenging salivary tumor subtypes. HER2 alterations, in
particular, are common in aggressive tumor subtypes, such
as SDCs.6,7 In the largest study of comprehensive molecular
proﬁling in salivary gland cancers, HER2 alterations occurred
in 32% of SDCs and 17% of other adenocarcinomas.6 The
high incidence of HER2 alterations and the efﬁcacy of HER2targeted therapy suggest similarities between SDC and
breast intraductal carcinomas. Salivary and mammary
glands share similar histogenetic origins; in addition to
frequent HER2 alterations, carcinomas arising from these
tissues share similar histology, morphology, and gene
expression proﬁles.22e25 These similarities, in addition to
the high response rate we observed in patients with HER2
ampliﬁed and/or overexpressing salivary gland carcinomas,
suggest that the success of HER2-targeted therapy in breast
cancer may extend to patients with HER2-positive salivary
gland carcinomas.
https://doi.org/10.1016/j.annonc.2019.11.018
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Limitations of this analysis include small patient cohorts
and non-blinded investigator assessments. In addition,
local molecular alteration testing was conducted at the
investigator’s discretion using site-determined methodology, with central genomic re-testing limited to two patients with available and sufﬁcient archival samples for
next-generation sequencing. Because of the limited sample size, the impact of co-mutations on efﬁcacy could not
be determined; this merits study in future investigations.
Although data from MyPathway suggest that targeted
therapy has potential in the treatment of SGC, the small
number of patients with this rare cancer may necessitate
additional study to assess efﬁcacy. Preliminary data from
other recent or ongoing basket trials have indicated
positive results for the targeted treatment of SGC with
trastuzumab emtansine (T-DM1), neratinib, vemurafenib,
entrectinib, and larotrectinib11e13,26e28; additional results
from these and other studies are anticipated.
Results from MyPathway provide a proof-of-principle for
matching patients to effective, chemotherapy-free treatment of tumors based on molecular characteristics rather
than site of origin, a particularly valuable opportunity for
cancer patients with limited treatment options or who are
unable to tolerate traditional chemotherapies.
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